ArticleScientific reports2025
Phage-mediated TLR2 signaling attenuates intracellular Mycobacterium abscessus survival in macrophages.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- When bacteriophages encounter macrophages during their journey through the human body.Frontiers in cellular and infection microbiology · 2026Review
- Innate immune recognition and immunomodulatory effects of bacteriophages: implications for phage therapy.Frontiers in immunology · 2026Review
- Phage therapy againstFrontiers in microbiology · 2026Review
- Filamentous Phage for Therapeutic Applications in Non-Small Cell Lung Cancer and Brain Metastases: Recent Prospect.International journal of nanomedicine · 2026Review
- Clinical and Translational Perspectives on Bacteriophage Therapy for Nontuberculous Mycobacterial Diseases.Journal of microbiology and biotechnology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The incidence of pulmonary infections caused by M. abscessus (MAB) is on rise globally. Despite susceptible infections, long-term, and combinational treatment, patients respond to MAB therapy only partially with low success rates. In recent years, therapeutic phages have been used in combination with antibiotics to enhance treatments for patients suffering with drug-resistant, chronic, and disseminated mycobacterial infections with favorable clinical outcomes. While phages are commonly recognized for their antimicrobial role through direct lysis of bacteria, expanding body of literature, describing phage interactions with the immune system, indicates that the therapeutic impact of phage may not solely hinge on lytic activity but also on stimulating innate immune responses. In this study, we aimed to uncover phages that work synergistically with macrophage cellular mechanisms, enhancing phagocyte-mediated reduction of intracellular MAB. We discovered phages stimulating TLR2 signaling associated with NLRP3 inflammasome activation, resulting in substantial attenuation of the intracellular pathogen growth. We also uncovered a new phenomenon of intracellular elimination of MAB through fusion of lytic phage vacuoles with bacterial phagosomes. This process is driven by a cellular mechanism triggered by phage exposure to phagocytic cells. New therapeutic characteristics of phage, described in this study, will contribute to future phage-based therapeutic interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.